肠道菌群及其代谢产物对冠心病影响的研究进展

doi:10.3969/j.issn.1003-9198.2021.09.019

摘要/Abstract

中图分类号:

R 541.4

陈梦琪, 刘正霞, 鲁翔. 肠道菌群及其代谢产物对冠心病影响的研究进展[J]. 实用老年医学, 2021, 35(9): 971-974.

[1] TANG W H W, KITAI T, HAZEN S L. Gut microbiota in cardiovascular health and disease[J]. Circ Res, 2017, 120(7):1183-1196.
[2] JANDHYALA S M, TALUKDAR R, SUBRAMANYAM C, et al. Role of the normal gut microbiota[J]. World J Gastroenterol, 2015, 21(29):8787-8803.
[3] SOMMER F, ANDERSON J M, BHARTI R, et al. The resilience of the intestinal microbiota influences health and disease[J]. Nat Rev Microbiol, 2017, 15(10):630-638.
[4] EMOTO T, YAMASHITA T, KOBAYASHI T, et al. Characterization of gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism: gut microbiota could be a diagnostic marker of coronary artery disease[J]. Heart Vessels, 2017, 32(1):39-46.
[5] CHAN Y K, BRAR M S, KIRJAVAINEN P V, et al. High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with Lactobacillus rhamnosus GG (LGG) or telmisartan in ApoE mice[J]. BMC Microbiol, 2016, 16(1):264.
[6] MALIK M, SUBOC T M, TYAGI S, et al. Lactobacillus plantarum 299v supplementation improves vascular endothelial function and reduces inflammatory biomarkers in men with stable coronary artery disease[J]. Circ Res, 2018, 123(9):1091-1102.
[7] BROWN J M, HAZEN S L. Microbial modulation of cardiovascular disease[J]. Nat Rev Microbiol, 2018, 16(3):171-181.
[8] WATANABE M, HOUTEN S M, MATAKI C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation[J]. Nature, 2006, 439(7075):484-489.
[9] DUBOC H, AELION H, RAINTEAU D, et al. Crosstalk between the hepatologist and the cardiologist: a future place for the lithocholic acid as a coronary atheroma risk factor[J]. Hepatology, 2012, 56(6):2426.
[10] 张琪, 宋晓鹏, 任茂佳, 等. 氧化三甲胺与心血管疾病的研究新进展[J]. 心血管病学进展, 2020, 41(1):81-84.
[11] CHEN M L, ZHU X H, RAN L, et al. Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway[J]. J Am Heart Assoc, 2017, 6(9):e006347.
[12] SENTHONG V, WANG Z, LI X S, et al. Intestinal microbiota-generated metabolite Trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort[J]. J Am Heart Assoc, 2016, 5(6):e002816.
[13] SCHIATTARELLA G G, SANNINO A, TOSCANO E, et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis[J]. Eur Heart J, 2017, 38(39):2948-2956.
[14] NEMET I, SAHA P P, GUPTA N, et al. A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors[J]. Cell, 2020, 180(5):862-877.
[15] TAN Y, ZHANG H, GUO D, et al. Adipophilin involved in lipopolysaccharide-induced inflammation in RAW264.7 cell via extracellular signal-regulated kinase 1/2-peroxisome proliferator-activated receptor gamma pathway[J]. DNA Cell Biol, 2017, 36(12):1159-1161.
[16] CHISTIAKOV D A, BOBRYSHEV Y V, KOZAROV E, et al. Role of gut microbiota in the modulation of atherosclerosis-associated immune response[J]. Front Microbiol, 2015, 6:671.
[17] MARQUES F Z, NELSON E, CHU P Y, et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice[J]. Circulation, 2017, 135(10):964-977.
[18] ESTHER L G, FERNANDO R A, LI T Y, et al. The Mediterranean-style dietary pattern and mortality among men and women with cardiovascular disease[J]. Am J Clin Nutr, 2014, 99(1):172-180.
[19] MANGELS D R, MOHLER E R. Catechins as potential mediators of cardiovascular health[J]. Arterioscler Thromb Vasc Biol, 2017, 37(1):757-763.
[20] LI D, WANG P, LUO Y, et al. Health benefits of anthocyanins and molecular mechanisms:update from recent decade[J]. Crit Rev Food Sci Nutr, 2017, 57(8):1729-1741.
[21] CHEN L, LIU W, LI Y, et al. Lactobacillus acidophilus ATCC 4356 attenuates the atherosclerotic progression through modulation of oxidative stress and inflammatory process[J]. Int Immunopharmacol, 2013, 17(1):108-115.
[22] PARCHURE N, ZOURIDAKIS E G, KASKI J C. Effect of azithromycin treatment onendothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection[J]. Circulation, 2002, 105(11):1298-1303.
[23] 罗晓雅, 杨志宏. 肠道菌群与心血管疾病相关性的研究进展[J]. 中国药理学通报, 2018, 34(8):1037-1041.
[24] WANG Z, ROBERTS A B, BUFFA J A, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis[J]. Cell, 2015, 163(7):1585-1595.
[25] BRUGÈRE J F, BORREL G, GACI N, et al. Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease[J]. Gut Microbes, 2014, 5(1):5-10.
[26] GREGORY J C, BUFFA J A, ORG E, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation[J]. J Biol Chem, 2015, 290(9):5647-5660.

肠道菌群及其代谢产物对冠心病影响的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

推荐阅读 10

[1]	顾崇怀, 项学军, 郑元喜, 乔锐, 林松. 达格列净对接受冠状动脉介入治疗的伴有射血分数降低的心力衰竭合并2型糖尿病老年病人疗效观察[J]. 实用老年医学, 2024, 38(10): 1025-1029.
[2]	徐寿勇, 袁勇. 老年病人开展双低剂量CT冠状动脉造影的可行性研究[J]. 实用老年医学, 2024, 38(10): 1054-1058.
[3]	查志敏, 刘欢, 王向明, 李秋爽, 郭妍. 心脏瓣膜钙化对老年冠心病病人预后的影响[J]. 实用老年医学, 2024, 38(3): 245-250.
[4]	朱晨晨, 秦海东. 斑块侵蚀在急慢性冠脉综合征发生发展中的作用[J]. 实用老年医学, 2024, 38(3): 308-311.
[5]	章颖, 谢玲, 叶佳琦, 羌文慧, 严晓云, 姜英, 张清. 层粘连蛋白与老年急性心肌梗死病人主要不良心血管事件的相关性[J]. 实用老年医学, 2024, 38(2): 149-151.
[6]	杨雪, 甯春, 赵娟, 郝敬波, 杨荣礼. 生长分化因子15和细胞因子对老年冠心病合并衰弱病人的诊断价值[J]. 实用老年医学, 2023, 37(10): 1009-1013.
[7]	郑亚国, 许田, 左广锋, 陈亮, 林松. 药物涂层球囊治疗老年冠状动脉分支开口病变病人的疗效观察[J]. 实用老年医学, 2023, 37(6): 599-602.
[8]	宋春梅, 尹亚娟, 刘永升, 郭岐峰, 陈洁, 魏梅. 焦虑对老年经皮冠状动脉介入治疗术后病人不良心血管事件的预测价值[J]. 实用老年医学, 2023, 37(4): 352-355.
[9]	黄多新, 周杰, 严凌, 李必龙, 叶露, 林松, 赵莹莹. 衰弱对老年冠心病病人心功能及PCI术并发症的影响[J]. 实用老年医学, 2023, 37(4): 395-397.
[10]	姜磊, 贾志强, 俞建, 李晓庆, 张冬梅, 黄菁菁. 强化瑞舒伐他汀治疗对老年急性冠脉综合征病人PCI术后炎性衰老相关指标的影响及临床疗效[J]. 实用老年医学, 2023, 37(3): 265-269.
[11]	王思佳, 韩旭. 老年稳定性冠心病合并颈动脉斑块中医药治疗研究进展[J]. 实用老年医学, 2023, 37(2): 109-111.
[12]	嵇佳林, 刘晶, 王雪黎, 冯泓琳, 韩旭. 冠心平片治疗冠心病的Meta分析和序贯分析[J]. 实用老年医学, 2023, 37(2): 128-133.
[13]	魏梅, 郭岐峰, 段立楠, 尹亚娟, 刘刚, 郑明奇, 刘永升. 亚临床甲状腺功能减退与老年病人经皮冠状动脉介入治疗术后死亡的相关性研究[J]. 实用老年医学, 2023, 37(2): 138-141.
[14]	姚俊秀, 郭进春, 郝小丹, 李龙心, 杨雪, 王璋. 慢性冠状动脉综合征病人肝细胞生长因子的表达及其诊断价值[J]. 实用老年医学, 2023, 37(2): 173-177.
[15]	张越, 李晓庆, 鲁翔. 脂蛋白相关磷脂酶A2在冠心病诊治方面的研究进展[J]. 实用老年医学, 2023, 37(2): 191-194.